Market overview
The global generic drugs market is worth USD 462 bn in 2026 and is forecast to reach USD 753 bn by 2036, growing at a 5.0% CAGR. United States is the largest country market and Oral solids is the largest by dosage form segment.
| Scope | Off-patent small-molecule medicines sold under generic names or as unbranded and branded generics, covering oral solids, injectables and inhalation products. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 440 bn |
| Value 2026 | USD 462 bn |
| Value 2036 | USD 753 bn |
| CAGR 2026-2036 | 5.0% |
| Volume 2026 | 99,254 million packs |
| Volume 2036 | 153,808 million packs |
| Average price 2026 | USD 4.66 per pack |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Generic Drugs market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 462 bn |
| 2027 | USD 485 bn |
| 2028 | USD 509 bn |
| 2029 | USD 535 bn |
| 2030 | USD 562 bn |
| 2031 | USD 590 bn |
| 2032 | USD 619 bn |
| 2033 | USD 650 bn |
| 2034 | USD 683 bn |
| 2035 | USD 717 bn |
| 2036 | USD 753 bn |
Generic Drugs market segmentation
By dosage form
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral solids | 62.0% | 59.1% | USD 286 bn | 4.5% |
| Injectables | 18.0% | 20.7% | USD 83.2 bn | 6.5% |
| Topical and ophthalmic | 8.0% | 7.6% | USD 37.0 bn | 4.5% |
| Inhalation and others | 12.0% | 12.6% | USD 55.4 bn | 5.5% |
By therapy area
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cardiovascular | 20.0% | 18.1% | USD 92.4 bn | 4.0% |
| Central nervous system | 17.0% | 16.9% | USD 78.5 bn | 5.0% |
| Anti-infectives | 13.0% | 11.8% | USD 60.1 bn | 4.0% |
| Oncology | 9.0% | 11.9% | USD 41.6 bn | 8.0% |
| Diabetes and metabolic | 11.0% | 11.5% | USD 50.8 bn | 5.5% |
| Other | 30.0% | 29.9% | USD 139 bn | 5.0% |
By distribution
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacy | 46.0% | 40.0% | USD 213 bn | 3.5% |
| Hospital pharmacy | 30.0% | 28.0% | USD 139 bn | 4.3% |
| Online and mail order | 24.0% | 32.0% | USD 111 bn | 8.1% |
By product type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Simple generics | 58.0% | 50.0% | USD 268 bn | 3.5% |
| Branded generics | 24.0% | 24.0% | USD 111 bn | 5.0% |
| Complex and specialty generics | 18.0% | 26.0% | USD 83.2 bn | 8.9% |
By payer
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Government-reimbursed | 38.0% | 40.0% | USD 176 bn | 5.5% |
| Private insurance | 34.0% | 32.0% | USD 157 bn | 4.4% |
| Out-of-pocket | 28.0% | 28.0% | USD 129 bn | 5.0% |
Top 25 countries for generic drugs by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 78.0% of 2026 revenue and the 25 countries below together hold 94.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 139 bn | 30.0% | USD 216 bn | 4.5% |
| 2 | China | USD 64.7 bn | 14.0% | USD 111 bn | 5.5% |
| 3 | Japan | USD 32.3 bn | 7.0% | USD 48.2 bn | 4.1% |
| 4 | India | USD 32.3 bn | 7.0% | USD 70.0 bn | 8.0% |
| 5 | Germany | USD 23.1 bn | 5.0% | USD 34.6 bn | 4.1% |
| 6 | France | USD 16.2 bn | 3.5% | USD 22.6 bn | 3.4% |
| 7 | Brazil | USD 16.2 bn | 3.5% | USD 30.1 bn | 6.4% |
| 8 | United Kingdom | USD 13.9 bn | 3.0% | USD 20.3 bn | 3.9% |
| 9 | Italy | USD 11.6 bn | 2.5% | USD 16.6 bn | 3.7% |
| 10 | Canada | USD 11.6 bn | 2.5% | USD 17.3 bn | 4.1% |
| 11 | Spain | USD 6.8 bn | 1.5% | USD 9.7 bn | 3.6% |
| 12 | Mexico | USD 6.8 bn | 1.5% | USD 12.1 bn | 5.9% |
| 13 | South Korea | USD 6.8 bn | 1.5% | USD 9.7 bn | 3.6% |
| 14 | Russia | USD 6.8 bn | 1.5% | USD 9.7 bn | 3.6% |
| 15 | Australia | USD 5.9 bn | 1.3% | USD 8.3 bn | 3.5% |
| 16 | Turkey | USD 5.9 bn | 1.3% | USD 10.4 bn | 5.9% |
| 17 | Indonesia | USD 5.9 bn | 1.3% | USD 12.4 bn | 7.8% |
| 18 | Poland | USD 3.9 bn | 0.8% | USD 5.5 bn | 3.4% |
| 19 | Netherlands | USD 3.9 bn | 0.8% | USD 5.5 bn | 3.4% |
| 20 | Saudi Arabia | USD 3.9 bn | 0.8% | USD 6.9 bn | 5.8% |
| 21 | Thailand | USD 3.9 bn | 0.8% | USD 6.9 bn | 5.8% |
| 22 | Egypt | USD 3.9 bn | 0.8% | USD 6.9 bn | 5.8% |
| 23 | Pakistan | USD 3.9 bn | 0.8% | USD 8.3 bn | 7.7% |
| 24 | Vietnam | USD 3.9 bn | 0.8% | USD 8.3 bn | 7.7% |
| 25 | Argentina | USD 2.9 bn | 0.6% | USD 4.1 bn | 3.6% |
| Rest of world | USD 26.3 bn | 5.7% | USD 41.5 bn | 4.7% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Teva
- Viatris
- Sandoz
- Sun Pharma
- Dr Reddys Laboratories
- Cipla
- Apotex
- Zentiva
Group 2: Regional and specialist players
- Aurobindo Pharma
- Lupin
- Zydus Lifesciences
- Hikma
- Fresenius Kabi
- Amneal
- Glenmark Pharmaceuticals
- Torrent Pharmaceuticals
- Intas Pharmaceuticals
- STADA
Group 3: Emerging and niche players
- Hengrui
- Qilu Pharmaceutical
- Alkem Laboratories
- Zhejiang Huahai Pharmaceutical
- CSPC Pharmaceutical
- Natco Pharma
- Granules India
- Ajanta Pharma
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the generic drugs market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.0% is calculated from the resulting values.
The market is divided by dosage form, by therapy area, by distribution, by product type, by payer. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the generic drugs market?
The global generic drugs market is estimated at USD 440 bn in 2025 and USD 462 bn in 2026.
How fast will the generic drugs market grow?
It is forecast to reach USD 753 bn by 2036, a compound annual growth rate of 5.0% from 2026, an increase of USD 291 bn.
Which country is the largest market for generic drugs?
United States is the largest market by revenue at USD 139 bn in 2026, 30.0% of the global total. The three largest countries together hold 51.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 8.0% a year from 2026 to 2036.
Which generic drugs segment is largest?
In the by dosage form split, Oral solids is the largest segment with 62.0% of 2026 revenue.
Who are the leading generic drugs companies?
Global leaders include Teva, Viatris, Sandoz, Sun Pharma.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Sterile InjectableUSD 454 bn · 8.5% CAGR
- BiologicsUSD 508 bn · 8.0% CAGR
- Hospital PharmacyUSD 509 bn · 6.3% CAGR
- Mental Health ServicesUSD 511 bn · 6.0% CAGR
- NutraceuticalUSD 516 bn · 7.5% CAGR
- Home HealthcareUSD 410 bn · 8.0% CAGR
- Specialty PharmacyUSD 523 bn · 8.5% CAGR
- TabletUSD 580 bn · 5.5% CAGR